Short Term
Mean Reversion
Neutral
Trend
Neutral
Event
Neutral
Halo Model
MQV
Very Strong
GARP
Very Strong
MQV Small
Neutral
Momentum
Price
Very Strong
Earnings
Very Strong
Growth
Earnings
Very Strong
Dividends
Very Strong
Quality
Capital Efficiency
Very Strong
Balance Sheet
Very Strong
Telephone
61.3.9801.8888
Address
Boronia 45 Wadhurst Drive Melbourne, Victoria (VIC) 3155
Description
IDT Australia Ltd. produces, develops and supplies pharmaceutical products. It engages in the provision of research and development and other technical services for the pharmaceutical and allied industries. The company specializes in the post-discovery pharmaceutical life cycle. It also provides services through API manufacturing, new drug development and scale-up, clinical research services, pharmacy services and finished dosage forms to the pharmaceutical industry. IDT Australia was founded by Graeme Leslie Blackman on October 14, 1975 and is headquartered in Melbourne, Australia.
Market Cap
PE
EV/EBITDA
DIV Yield
Franking
Ex Dividend Date (est.)
52 weeks range
Low 0.05 - 0.13
Trade Value (12mth)
AU$5,521.00
1 week
1.45%
1 month
-28.57%
YTD
-33.33%
1 year
-39.13%
All time high
2.80
EPS 3 yr Growth
302.10%
EBITDA Margin
-36.90%
Operating Cashflow
-$6m
Free Cash Flow Return
-22.80%
ROIC
-29.40%
Interest Coverage
-9.30
Quick Ratio
2.40
Shares on Issue (Fully Dilluted)
424m
HALO Sector
Healthcare
Next Company Report Date
01-Sep-26
Ex Dividend Date (est.)
N/A
Next Dividend Pay Date (est.)
N/A
Reporting Currency
AUD
Short Sell (% of issue)
0.00
Date | Announcements |
---|---|
21 August 25 |
FY25 Appendix 4E and Annual Report
×
FY25 Appendix 4E and Annual Report |
21 August 25 |
FY25 Appendix 4G and Corporate Governance Statement
×
FY25 Appendix 4G and Corporate Governance Statement |
21 August 25 |
FY25 Full Year Profit Results
×
FY25 Full Year Profit Results |
19 August 25 |
Planned Retirement of the Chief Financial Officer
×
Planned Retirement of the Chief Financial Officer |
07 August 25 |
CEO Resignation & Trading Update
×
CEO Resignation & Trading Update |
05 August 25 |
Trading Halt
×
Trading Halt |
17 July 25 |
Agreement with NASDAQ-Listed Gelteq for Dedicated Facility
×
Agreement with NASDAQ-Listed Gelteq for Dedicated Facility |
15 July 25 |
Notification of cessation of securities - IDT
×
Notification of cessation of securities - IDT |
29 April 25 |
Quarterly Revenue Growth of 30% with $62M in Open Proposals
×
Quarterly Revenue Growth of 30% with $62M in Open Proposals |
14 April 25 |
Change of Director's Interest Notice - Geoffrey Sam
×
Change of Director's Interest Notice - Geoffrey Sam |
09 April 25 |
New $3.2M Contract Supports Australia's Largest API Plant
×
New $3.2M Contract Supports Australia's Largest API Plant |
04 March 25 |
Notification of cessation of securities - IDT
×
Notification of cessation of securities - IDT |
25 February 25 |
1HFY25 Results Presentation
×
1HFY25 Results Presentation |
19 February 25 |
1HFY25 Appendix 4D and Half Year Report
×
1HFY25 Appendix 4D and Half Year Report |
19 February 25 |
1HFY25 Results
×
1HFY25 Results |
13 February 25 |
Notification of cessation of securities - IDT
×
Notification of cessation of securities - IDT |
06 February 25 |
Notification of cessation of securities - IDT
×
Notification of cessation of securities - IDT |
28 January 25 |
Further Growth in Q2 - H1FY25 Revenue Expected to Jump 82%
×
Further Growth in Q2 - H1FY25 Revenue Expected to Jump 82% |
24 January 25 |
Settlement of Loan Facility with ScotPac
×
Settlement of Loan Facility with ScotPac |
20 December 24 |
IDT Secures new loan Facility with ScotPac
×
IDT Secures new loan Facility with ScotPac |
19 November 24 |
2024 AGM Presentation
×
2024 AGM Presentation |
19 November 24 |
AGM Results of Meeting
×
AGM Results of Meeting |
13 November 24 |
Termination of discussions with Mynd
×
Termination of discussions with Mynd |
21 October 24 |
Q1 FY25 Quarterly Unaudited Revenue Hits Two-Year High
×
Q1 FY25 Quarterly Unaudited Revenue Hits Two-Year High |
18 October 24 |
Notice of Annual General Meeting
×
Notice of Annual General Meeting |
Load More
Load Less
Percent of Issue
Value ($M)
Prior Change
7 Day Change
1 Month Change
3 Month Change
Access data on short interest, stock performance, and potential short-selling candidates across various markets to make informed decisions and optimize your trading strategies.
Unlock true investor intelligence
Research, trade and manage global markets from one place with HALO Global. It’s trading - the way you want it.
Get the latest insights and hot tips delivered right to your inbox
HALO Technologies Pty Ltd ABN 54 623 830 866 is a Corporate Authorised Representative No 1261916 of Macrovue Pty Ltd ABN 98 600 022 679 AFSL 484264. Macrovue Pty Ltd is a wholly owned subsidiary of HALO Technologies Pty Ltd.